Grant Thornton expands Brisbane tax with new appointment
Lane brings more than 20 years of experience in corporate tax advisory, having worked in-house, as an external consultant, and at two Big Four professional services firms.
Lane's specialist experience in the financial services industry includes leadership roles in the tax and finance teams of a 'large' Australian superannuation fund, the professional services provider said.
His expertise spans superannuation, insurance, funds management, and banking.
Additionally, Lane has knowledge of tax matters related to financing arrangements, thin capitalisation, capital management, global tax compliance, and tax governance reviews.
Lane's proficiency extends to providing transactional tax support, including tax due diligence, restructuring, and both domestic and international tax structuring advice.
He also offers other M&A advisory services, catering to a clientele, including corporate groups, investment funds, and high-net-worth family offices.
Grant Thornton head of tax in Brisbane Tim Hands said: 'Matt's business acumen, alongside his broad tax and financial services industry expertise and ability to navigate complex tax landscapes is a welcome addition to our team and will complement our already extensive client service offering.'
Grant Thornton partner of corporate tax Matthew Lane said: 'I am excited to be joining Grant Thornton's Brisbane tax team and bring my specialist experience to add value to clients.
'I am particularly passionate about financial services and the future of fintech so it's pleasing to be able to apply my experience in a corporate tax setting. There's so much potential for change and growth in the Brisbane Fintech market and I am eager to have the opportunity to see the industry change and grow.'
Last week, Grant Thornton UK collaborated with Teesside University to launch a skills development initiative.
The 'AI and Digital Skills for Business Impact' programme aims to enhance key competencies within businesses.
It focuses on digital technologies, change management, business process modelling, data essentials, and AI for operational improvements.
The programme, co-developed by professionals from Grant Thornton and Teesside University, supports employees across different levels of experience and career progression.
"Grant Thornton expands Brisbane tax with new appointment " was originally created and published by International Accounting Bulletin, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
By Bhanvi Satija (Reuters) -The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said on Monday. The added costs could raise prices for consumers unless pharmaceutical companies take action to mitigate the impact of the tariffs, one of the analysts said. Pharmaceuticals had historically been exempt from duties. Medicines are the largest European exports to the United States by value and the EU accounts for about 60% of all pharmaceutical imports to the U.S. On Sunday, European officials said that a bilateral trade deal for an across-the-board 15% tariff included pharmaceuticals, except for some generic drugs, which would be subject to no tariffs. The U.S. has been conducting a national security investigation into the pharmaceutical sector and the industry has been bracing for separate sectoral tariffs. President Donald Trump said earlier this month, before negotiating the bilateral deal, that pharmaceutical tariffs could be as high as 200%. Some Wall Street analysts said that they do not expect additional tariffs on the EU as a result of the investigation, but others cautioned that the deal was not yet signed and that several questions remained unanswered. UBS analyst Matthew Weston said that he expects details of the trade deal to include protective measures for EU pharma exports from the U.S. investigation, especially since such measures are being discussed in negotiations with the United Kingdom and Switzerland. ING analyst Diederik Stadig also said that while tariffs on top of the 15% were not expected, even after the conclusion of the national security investigations, nothing is completely clear "until a trade deal is inked." Stadig estimates that these levies could add $13 billion to industry expenses without any mitigation strategies, and some of that could be ultimately borne by the consumer. Bernstein analyst Courtney Breen puts the additional expenses at $19 billion for the industry, but she notes that companies might be able to absorb some of the costs with the measures they have been implementing — such as stockpiling of drug products and new deals with contract researchers. Earlier this month, Sanofi said it will sell a manufacturing facility in New Jersey to Thermo Fisher, where the French drugmaker's therapies will continue to be manufactured. Roche's CEO Thomas Schinecker said last week that the company was increasing its U.S. inventories to avoid any immediate disruption from tariffs. UBS' Weston said that it was not immediately clear which generic drugs were exempted from duties under the deal, but any impact for generic drugmaker Sandoz for this year should mostly be manageable. Shares in pharmaceutical companies Sanofi, Roche and Sandoz Group all closed up between 0.5% and 1% on Monday. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
By Bhanvi Satija (Reuters) -The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said on Monday. The added costs could raise prices for consumers unless pharmaceutical companies take action to mitigate the impact of the tariffs, one of the analysts said. Pharmaceuticals had historically been exempt from duties. Medicines are the largest European exports to the United States by value and the EU accounts for about 60% of all pharmaceutical imports to the U.S. On Sunday, European officials said that a bilateral trade deal for an across-the-board 15% tariff included pharmaceuticals, except for some generic drugs, which would be subject to no tariffs. The U.S. has been conducting a national security investigation into the pharmaceutical sector and the industry has been bracing for separate sectoral tariffs. President Donald Trump said earlier this month, before negotiating the bilateral deal, that pharmaceutical tariffs could be as high as 200%. Some Wall Street analysts said that they do not expect additional tariffs on the EU as a result of the investigation, but others cautioned that the deal was not yet signed and that several questions remained unanswered. UBS analyst Matthew Weston said that he expects details of the trade deal to include protective measures for EU pharma exports from the U.S. investigation, especially since such measures are being discussed in negotiations with the United Kingdom and Switzerland. ING analyst Diederik Stadig also said that while tariffs on top of the 15% were not expected, even after the conclusion of the national security investigations, nothing is completely clear "until a trade deal is inked." Stadig estimates that these levies could add $13 billion to industry expenses without any mitigation strategies, and some of that could be ultimately borne by the consumer. Bernstein analyst Courtney Breen puts the additional expenses at $19 billion for the industry, but she notes that companies might be able to absorb some of the costs with the measures they have been implementing — such as stockpiling of drug products and new deals with contract researchers. Earlier this month, Sanofi said it will sell a manufacturing facility in New Jersey to Thermo Fisher, where the French drugmaker's therapies will continue to be manufactured. Roche's CEO Thomas Schinecker said last week that the company was increasing its U.S. inventories to avoid any immediate disruption from tariffs. UBS' Weston said that it was not immediately clear which generic drugs were exempted from duties under the deal, but any impact for generic drugmaker Sandoz for this year should mostly be manageable. Shares in pharmaceutical companies Sanofi, Roche and Sandoz Group all closed up between 0.5% and 1% on Monday.
Yahoo
an hour ago
- Yahoo
DoorDash Hires Spotify Advertising Head as Chief Revenue Officer
(Bloomberg) -- DoorDash Inc. has hired Spotify Technology SA Global Head of Advertising Lee Brown as chief revenue officer. Can This Bridge Ease the Troubled US-Canadian Relationship? Budapest's Most Historic Site Gets a Controversial Rebuild Trump Administration Sues NYC Over Sanctuary City Policy Brown will start in late August and report to DoorDash Chief Operating Officer Prabir Adarkar, according to a company spokesperson. Brown will oversee revenue across the main business lines of restaurant, retail, grocery and emerging categories in the US, Canada, Australia and New Zealand, the spokesperson added. He will also lead sales and sales operations, merchant strategy and operations, and partner closely with Head of Ads Toby Espinosa, who continues to report to Adarkar. 'Spotify and Lee Brown have mutually agreed to part ways,' according to a Spotify spokesperson. Brown led the audio streamer's $2 billion ads business across nearly 90 markets internationally, overseeing sales, business development, marketing, product and engineering functions. At DoorDash, he will fill the role of Tom Pickett, who left the company last August to become chief executive officer of meditation app Headspace Inc. DoorDash, which has two-thirds of the US food-delivery market, announced in June that it had acquired advertising tech firm Symbiosys for $175 million to bolster a business that generates more than $1 billion a year. The deal lets the company offer its advertisers the ability to manage their marketing messages on external sites such as social media, in addition to the DoorDash app and website. Spotify is set to report second-quarter results Tuesday, while DoorDash is scheduled to release its results on Aug. 6. Axios earlier reported Brown's hiring by DoorDash. --With assistance from Ashley Carman. Burning Man Is Burning Through Cash It's Not Just Tokyo and Kyoto: Tourists Descend on Rural Japan Elon Musk's Empire Is Creaking Under the Strain of Elon Musk Confessions of a Laptop Farmer: How an American Helped North Korea's Wild Remote Worker Scheme Cage-Free Eggs Are Booming in the US, Despite Cost and Trump's Efforts ©2025 Bloomberg L.P.
